Phase 2 N=30 Cellular Therapy With Cord Blood Cells
Multiple Myeloma · Leukemia · Lymphoma
Primary: Number of Participants With Engraftment — 27 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=48 Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
Sarcoma · Oral Mucositis
Primary: Cumulative Incidence Rate of Oral Mucositis — 44; 88; 13; 51 Percentage of Participants — p=<0.001
Phase 2 N=113 A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants With a Tumor Response (Objective Tumor Response Rate) — 38.5 percentage of participants
Phase 2 N=7 An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain
Chronic Refractory Neuropathic Pain
Primary: Number of Subjects Reporting At Least 1 Treatment-Emergent Adverse Event (TEAE) During The Treatment Period. — 7 participants
Phase 2 N=40 Efficacy of AMALS in Treating Language Impairment in Children
Language Disorder
Primary: Language Sample Analysis — 17.33; 18.00; 39.35; 26.38 Percentage of utterances
Phase 2 N=196 Busulfan and Fludarabine in Patients With AML and MDS
Leukemia
Primary: Number of Participants With Successful Engraftment — 192 participants
Phase 2 N=94 Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus
Type 2 Diabetes
Primary: Continuous Glucose Monitoring (CGM) — -6.23; -0.72 Percentage of day (24h) in euglycemia
Phase 2 N=298 A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine
Breast Cancer
Primary: Objective Response Rate — 14.1 Percentage of Participants
Phase 2 N=108 Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Prostate Cancer
Primary: Objective Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria — 16.2; 52.4; 29.5; 1.9 Percentage of Participants
Phase 2 N=58 Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy
Postoperative Pain
Primary: Time to First Use of Supplemental Pain Medication Postoperatively for Surgical Pain — 9.4; 1.9; 1.2; 2.4 hours
Phase 2 N=76 Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair
Inguinal Hernia
Primary: Time to First Use of Supplemental Pain Medication — 4.2; 13.75; 3.9; 5.2 hours
Phase 2 N=10 Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
Breast Cancer · Breast Neoplasms
Primary: Objective Response (Complete Clinical Response+ Partial Response) — 20 percentage of patients
Phase 2 N=30 Post Stroke Hand Functions: Bilateral Movements and Electrical Stimulation Treatments
Cerebrovascular Accident · Hemiplegia
Primary: Box and Block Test; Data Collected = Number of Blocks Moved — 24.5; 24.6; 40; 27.5 Blocks — p=<0.05
Phase 2 N=15 GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
Prostate Cancer
Primary: Time to Disease Progression (TTP) — 6; 11 months
Phase 2 N=33 Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Leukemia
Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants